Matt Fornataro's practice focuses on life sciences and health care regulation, and he specializes in drug pricing and government price reporting, market access strategies, and fraud and abuse compliance. Matt works with established and emerging pharmaceutical, biotechnology, and medical device manufacturers.
In his work on government price reporting matters, Matt advises manufacturers on Medicaid, Medicare Part B, Department of Veterans Affairs, and 340B Program requirements, as well as state drug price reporting and transparency laws. He also advises on implementation of the drug pricing provisions of the Inflation Reduction Act of 2022, including the Maximum Fair Price program.
Matt also supports manufacturers with market access strategies and contracting, including advising on fraud and abuse compliance. He addresses questions arising under the federal Anti-Kickback Statute, the False Claims Act, and the Civil Monetary Penalties & Exclusion laws. Matt assists manufacturers with complex risk analyses, internal reviews and investigations, OIG Advisory Opinion requests, product acquisitions and divestitures, and government audits and investigations.
He is Co-Chair of Arnold & Porter's Pride Affinity Group for LGBTQ+ attorneys, and serves as a member of the Firm's Diversity & Inclusion Committee. Matt was named by the National LGBT Bar Association as one of its 2014 "Best LGBT Lawyers Under 40" for his professional accomplishments and pro bono work for causes of importance to the LGBTQ+ community.
Experience
- Assist manufacturers with implementation of the drug pricing provisions of the Inflation Reduction Act of 2022, including the implications of the Medicare rebate programs and drug price negotiation.
- Provide day-to-day counsel to manufacturers on drug price reporting compliance issues.
- Prepare comprehensive government price reporting policies and reasonable assumptions.
- Advise clients on drug pricing restatements.
- Draft comments for manufacturers on the Inflation Reduction Act, the Medicaid Drug Rebate Program, and the 340B Program proposed rules and guidance.
- Coordinate business-focused trainings on government price reporting compliance issues, including discounting, bundled sales, Best Price stacking, and value-based purchasing arrangements.
- Advise on pending legislation, regulatory reforms, and Congressional investigations.
- Represented the Pharmaceutical Research and Manufacturers of America (PhRMA) in two successful challenges to the legality of the Health Resources and Services Administration’s Orphan Drug Exclusion Final Rule and subsequent interpretive rule. See Pharmaceutical Research and Manufacturers of America v. U.S. Dep’t of Health and Human Servs., et al., 13-cv-1501 (D.D.C. May 23, 2014) and Pharmaceutical Research and Manufacturers of America v. U.S. Dep’t of Health and Human Servs., et al., 14-cv-1685 (D.D.C. October 14, 2015).
Perspectives
Recognition
Credentials
Education
- J.D., University of Pittsburgh School of Law, 2008
- B.A., English and Philosophy, Bucknell University, 2005, magna cum laude
Admissions
- District of Columbia
- Pennsylvania